Background {#Sec1}
==========

The Total Exposure Study (TES) was designed by a tobacco company sponsor in the 1990s with the primary objectives of estimating exposure of current U.S. adult cigarette smokers to cigarette smoke constituents and of investigating relationships between FTC tar categories and cigarette smoke exposure. Other objectives included investigating associations of smoking behavior and biomarkers of exposure (BOE), comparing BOE in adult smokers and non-users, and investigating relationships between BOE and biomarkers of potential harm (BOPH) \[[@CR1]\]. From 2002 to 2003, internationally-recognized contract research organizations (CROs), under contract to the tobacco company sponsor, collected questionnaire data, clinical data, and biological samples from 3,585 smokers and 1077 non-users at 39 clinical sites in 31 U.S. states and performed clinical chemistry, laboratory and statistical analyses \[[@CR1]--[@CR3]\]. TES participants were recruited using Institutional Review Board-approved advertisements \[[@CR1], [@CR2]\], with defined inclusion and exclusion criteria (Additional file [1](#MOESM1){ref-type="media"}). The study was approved by an Institutional Review Board at each clinical site and conducted in accordance with Good Clinical and Laboratory Practices and principles of the Declaration of Helsinki. Using blood and urine biospecimens and mass spectrometry-based and clinical chemistry-based analyses, the CROs determined levels of BOE and BOPH in smokers and non-users. Additional blood and urine biosamples were collected from consenting subjects for possible future analyses.

The Virginia Tobacco Health Research Repository (VTHRR) was formed in 2010 as a Virginia non-profit, non-stock corporation by authorization of the Virginia BioTechnology Research Partnership Authority Board, a political subdivision of the Commonwealth of Virginia. The VTHRR received TES data and biospecimens as a contribution from the tobacco company sponsor. The mission of the VTHRR is to make the TES data and banked biospecimens available to scientists, research institutions, regulatory agencies and industry for research to increase the scientific knowledge base of the health effects of cigarette smoking \[[@CR4]\].

Under a 2012 Asset Transfer Agreement between the VTHRR and SRI International (SRI), an independent, non-profit research institute incorporated in 1946 in the state of California, TES data and biospecimens were transferred to SRI in 2012. The agreement between SRI and VTHHR provides SRI with complete independence to pursue valid scientific objectives. The principal intended result of any analysis of TES data or biospecimens is the generation of knowledge related to smoking and health that is shared in the scientific peer-reviewed literature and in appropriate databases. SRI will independently maintain, curate, and make both data and biospecimens available to the research community for this purpose.

In order to optimize the validity and utility of the TES data and banked biospecimens to support its full use by the global public health research community, there is a need for thoughtful, objective scientific analysis of the resource. The purpose of this analysis was to review TES data and biospecimens, investigate distributions of self-reported, clinical and laboratory measures of exposure and potential harm (biomarker), and pote\`ntial differences in biomarker levels between those participants with banked biospecimens and those without, calculate statistical power for genomic analyses, and perform analyses of plasma and peripheral blood monocyte analytes.

Methods {#Sec2}
=======

We obtained ethical approval from the SRI International Human Subjects Committee to conduct these analyses of TES data and biospecimens.

Each study site selected to use either their individual site-specific IRB or a central IRB contracted by the primary clinical and laboratory CRO responsible for the conduct of the study. TES participants were recruited, provided informed consent and were screened in a two-visit, multicenter process as current cigarette smokers, stratified by their regular cigarette's Federal Trade Commission (FTC) tar level (≤2.9, 3.0--6.9, 7.0--12.9, and ≥ 13 mg), and as non-users \[[@CR1], [@CR2]\]. Inclusion and exclusion criteria are described in Additional file [1](#MOESM1){ref-type="media"}. Participants were paid up to 300 U.S. dollars for completion of all study components. Recruitment sites were distributed in 31 States over four regions \[Midwest (19.7 %), Northeast (13.0 %), South (37.8 %) and West (29.5 %)\] and among urban (68.5 %) and non-urban (31.5 %) areas.

All participants provided vital signs (at both visits), medical history and concomitant medication data (at the first visit), and completed a questionnaire survey regarding smoking history and attitudes and preferences regarding smoking (in current smokers), demographics, lifestyle and environmental exposures (at the second visit). Between the first and second visit, smokers collected cigarette butts over a 24-h period and smoking topography information using a portable instrument which measured the number of puffs, the length of puffs and the length of the inter-puff interval. Both smokers and non-users collected their urine over 24-h. At the second visit, lung function tests were performed and blood was collected for processing, biomarker assays and, under a separate consent for future research, for banking.

Four tubes of whole blood \[two 10 ml potassium ethylenediaminetetraacetic acid (KEDTA) and two 8.5 ml acid citrate dextrose solution A (ACDA) tubes\] were obtained from each participant at the second visit after a minimum 6 h fast and processed for plasma, red blood cells and monocytes \[[@CR1]\]. The TES biospecimen aliquots in SRI's possession include approximately: a) 6000 peripheral blood mononuclear cell (PBMC) samples; b) 7000 red blood cell samples; c) 5000 24-h urine samples; and d) 3000 plasma samples. TES biospecimens have been stored at −80 °C by the VTHRR and SRI.

We examined TES publications, accessed the University of California San Francisco Legacy Tobacco Documents Library (UCSF LTDL) website \[[@CR5]\] TES-related documents to 1) compare with documents we had received from the VTHRR and 2) to learn more about the study design and analysis goals of the TES, and engaged with colleagues regarding the potential value of the TES for tobacco research. We reviewed data collection, sample preservation, and laboratory assay protocols followed by the CROs that conducted the TES. We inspected TES clinical and biospecimen data and labeled biospecimens to confirm that the dataset was deidentified.

We queried the TES clinical data to assess the distribution of participant data among the analysis strata (age, sex, and BMI) among the four smoking categories defined by the smoker's usual cigarette FTC tar level, and among non-users. We evaluated the distributions of analysis strata among all participants, by banked biospecimen availability, and by biospecimen type. We analyzed additional behavioral, demographic, biomarker and tobacco product variable distributions among participants, and compared distributions between participants with and without banked biospecimens.

We constructed logistic regression models predicting the availability of biospecimens in self-identified non-Hispanic Black and White smokers using individuals with complete data in three increasingly complex models. Model 1 comprised BMI and demographic covariates, Model 2 added BOE to the covariates in model 1, and Model 3 added BOPH to Model 2. We imputed missing data for each model and repeated analyses with the larger sample sizes. To determine the extent to which random variability was responsible for the ability of the demographic variables and biomarkers to predict biospecimen availability, we randomly permuted the variable indicating the availability of biospecimens and determined a 95 % confidence interval for the percent reduction in the variance of this randomly permuted variable attributable to the covariates.

Plasma biospecimens were randomly selected (women and men, aged 35--49 years, with BMI \< 25 kg/m^2^, both current smokers and non-users) and sent to the SRI Clinical Analysis Laboratory (CAL). Six clinical laboratory assays were performed on 47 plasma samples to measure levels of glucose, aspartate and alanine aminotransferases, total bilirubin, albumin, and total cholesterol. We estimated the correlation between SRI CAL plasma and original CRO serum analyte values.

PBMCs randomly selected from TES participants (*N* = 30, \~1 % of participants with available biospecimens) from defined strata \[ages 35--49 and with BMI \< 25 kg/m^2^\] resulted in a sample that was 37 % female, 70 and 20 % self-identified White and Black, with 67 % current smokers. Initially, we performed DNA extraction from a limited number of pellets using Gentra Puregene reagents (Qiagen). To conserve biospecimen resources, we reviewed several multiple analyte protocols, and selected a protocol for simultaneous DNA and RNA extraction (NORGEN 48700 kit with Proteinase K). We modified lysis buffer amounts by available white blood cell count data and extracted \~1X10^6^ cells from each lysed pellet. DNA was sent to the Rutgers University Cell and DNA resource for genotyping with the Smokescreen® Array \[[@CR6]\]. RNA quality (RNA integrity score, RIN) was analyzed using the Agilent 2100 BioAnalyzer using the Eukaryote Total RNA Nano assay.

Statistical analyses were performed using SAS version 9.2 (Cary, North Carolina) and STATA SE version 12.0 (Stata Corp, College Station, Texas). Except where specified, the alpha used for statistical significance was 0.05. We evaluated power to detect genetic variants for serum cotinine at genome-wide significance using Quanto \[[@CR7]\].

Results {#Sec3}
=======

Review of the published TES literature {#Sec4}
--------------------------------------

Scientists employed by the tobacco company sponsor have published analyses in peer-reviewed scientific journals using data from the TES pilot study \[[@CR8]\] and the TES main study \[[@CR2], [@CR3], [@CR9]--[@CR16]\]. Analyses included population estimates of BOE levels for smokers and non-users \[[@CR2]\], estimates of levels of BOPH in smokers and non-users \[[@CR3]\], the relationships between machine-derived tar yields of cigarette products and BOE in smokers \[[@CR9]\], models of BOPH \[[@CR11]\], the impact of menthol-containing cigarettes on selected BOE in White and Black smokers \[[@CR10]\], and the relationships between selected BOE and BOPH in smokers \[[@CR14]\]. These scientists have also reported on the relationships between BOE and nicotine dependence \[[@CR13]\] and between nicotine and carbon monoxide BOE and other factors, including smoking topographical variables \[[@CR12]\]. These authors utilized TES data to examine the relationships between smoking mentholated cigarettes or non-mentholated cigarettes and glucuronide metabolite ratios \[[@CR15]\], and with measures of nicotine dependence \[[@CR16]\]. We review Roethig *et al.* \[[@CR2]\] and Frost-Pineda *et al.* \[[@CR3]\] here to introduce TES BOE (Additional file [2](#MOESM2){ref-type="media"}: Table S1) and BOPH (Additional file [3](#MOESM3){ref-type="media"}: Table S2).

Roethig *et al.* published estimates of BOE (Additional file [2](#MOESM2){ref-type="media"}: Table S1) in smokers and non-users and, within smokers, within different age, sex, BMI, and self-identified racial strata \[[@CR2]\]. Mean levels of BOE were weighted by age, sex and BMI variance estimates from the U.S. Behavioral Risk Factor Surveillance System (BRFSS), an annual telephone-based behavioral survey established in 1984 \[[@CR17]\], to produce weighted estimates of BOE reported and described by Roethig *et al.* as population estimates \[[@CR2]\]. The BRFSS used post-stratification weighting based on United States Census data from the 1980s until 2011 \[[@CR17]\]. Lee and Messiah criticized the application of weights extracted from a nationally representative sample to a sample for which inclusion rates at recruitment sites were not known or not reported \[[@CR18]\]. In response, Sarkar and Liang noted that the weighted means were similar to or unchanged from unadjusted means \[[@CR19]\]. Weighted estimates of tobacco-specific biomarkers \[nicotine, cotinine and trans-3′-hydroxycotinine and their glucoronides (nicotine equivalents, NE), serum cotinine, and total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and glucuronide (total NNAL)\] suggested that the younger participants (21--34 years) and female participants had the lowest tobacco-specific exposures, and that individuals with BMIs \< 25 kg/m^2^ compared with individuals with BMIs ≥ 25 kg/m^2^ had higher serum cotinine levels and lower total NNAL levels, suggesting reduced cotinine clearance and NNK metabolism in heavier individuals \[[@CR2]\]. Significant differences in serum cotinine by BMI similar to those reported in the TES have been previously observed in the National Health and Nutrition Examination Survey \[[@CR20]\]. In the TES, self-identified White smokers smoked significantly more cigarettes per day and had greater NE and total NNAL exposure over 24 h, but lower NE and total NNAL exposure per cigarette, and lower serum cotinine exposure, than self-identified Black smokers \[[@CR2]\]. It has previously been observed that White smokers smoke more cigarettes per day than Black smokers and that nicotine intake per cigarette measured by serum cotinine is higher in Black smokers than in White smokers \[[@CR21], [@CR22]\], which is related to significantly reduced nicotine clearance in Blacks compared to Whites \[[@CR23], [@CR24]\].

Frost-Pineda *et al.* \[[@CR3]\] reported mean values for 29 BOPH (Additional file [3](#MOESM3){ref-type="media"}: Table S2) in both smokers and non-users. The BOPH represented various physiological functions: cardiovascular, endothelial, hematologic, inflammation, lipid, hepatic, renal, respiratory, metabolic, and oxidative stress \[[@CR3]\]. The effects of multiple BOE \[cigarettes per day (CPD), NE, and smoking duration\] on the BOPH in current smokers versus non-users were evaluated in two stepwise regression models (model A with CPD and smoking duration, and model B with NE and smoking duration) with age, sex, BMI and self-identified race as additional independent variables \[[@CR3]\]. The three most elevated mean BOPH in current smokers versus non-users were those reflecting oxidative stress, platelet activation and inflammation. The oxidative stress biomarker 8-epi-prostaglandin F~2α~ exhibited the largest difference between smokers and non-users (+42 %), while BMI and age, and BMI and NE, were the most important correlates in models A and B, respectively. The platelet activation biomarker 11-dehydrothromboxane B~2~ exhibited the second largest difference between smokers and non-users (+29 %), and sex and BMI, and sex and NE were the most important correlates in models A and B, respectively. The inflammation biomarker white blood cell count exhibited the third largest difference between smokers and non-users (+19 %) and BMI and self-identified race were the most important correlates in both models. Overall, BMI and sex were the first and second most common significant correlates reported by Frost-Pineda *et al.* \[[@CR3]\].

Our search of the UCSF LTDL identified multiple documents we had received from the VTHRR, including: the Amended Final Research Protocol, dated 19 August 2002, that describes the clinical protocol, laboratory testing and biospecimen banking procedures to be conducted by the primary clinical and laboratory CRO \[[@CR1]\]; the TES Adult Smoker Survey \[[@CR25]\]; and the TES Adult Non-Smoker Survey \[[@CR26]\]. We found no differences between the documents we had received from VTHRR and those available on the UCSF LTDL. We also identified summary documents that provided information on the design and analysis goals of the TES, including: a Statement of Work for data management and analysis to be conducted by the primary data analysis CRO dated 30 April 2004 \[[@CR27]\]; a draft version of the Statistical Analysis Plan dated 1 September 2004 \[[@CR28]\]; and a PowerPoint presentation dated 7 February 2005 that presented TES pilot results, and design and initial analyses of the TES \[[@CR29]\]. Review of these documents enriched our understanding of the design and conduct of the study and confirmed study parameters, e.g., numbers of individuals recruited within design strata. With the assistance of a UCSF Industry Documents Digital Librarian, we identified SAS datasets available in the Philip Morris collection but these refer to an unrelated study \[[@CR30]\].

TES recruitment and analysis strata {#Sec5}
-----------------------------------

The original enrollment goal of the TES \[[@CR1]\] was 1000 smokers among four strata defined by FTC tar levels of the smoker's usual cigarette (≤2.9, 3--6.9, 7--12.9, and ≥ 13 mg), and 1000 non-users \[[@CR1]\]. The distribution of evaluable subjects in the five categories (504, 953, 1066, and 1062 smokers, and 1077 non-users) was significantly different from the design (Pearson *χ*^2^~4d.f.~ = 159.9, *P* \< 0.0001). The distribution of participants with clinical data by enrollment strata and by demographic strata is shown in Table [1](#Tab1){ref-type="table"}.Table 1TES participants with clinical data, by recruitment variables and by previously utilized analysis strataAnalysis Variable≤2.9 mg3.0--6.9 mg7.0--12.9 mg≥13 mgSmokers^a^Non-users^b^SexFemale293 (58.1)648 (68.0)604 (56.7)514 (48.4)2059 (57.4)639 (59.3)N (%)Male211 (41.9)305 (32.0)462 (43.3)548 (51.6)1526 (42.6)438 (40.7)Age, years21--3482 (16.3)273 (28.6)397 (37.2)387 (36.4)1139 (31.8)358 (33.2)N (%)35--49224 (44.4)394 (41.3)377 (35.4)428 (40.3)1423 (39.7)358 (33.2)≥50198 (39.3)286 (30.0)292 (27.4)247 (23.3)1023 (28.5)361 (33.5)BMI (kg/m^2^)\<25177 (35.1)392 (41.1)425 (39.9)411 (38.7)1405 (39.2)398 (37.0)N (%)≥25327 (64.9)561 (58.9)641 (60.1)651 (61.3)2180 (60.8)679 (63.0)Total504 (14.1)953 (26.6)1066 (29.7)1062 (29.6)3585 (76.9)1077 (23.1)^a^Participants smoking ≥ one manufactured cigarette per day during the last year. ^b^Non-users of tobacco or nicotine products for the last five years, and throughout the study

TES demographics and smoking status {#Sec6}
-----------------------------------

The demographic composition of TES participants with clinical data (*N* = 4662) was 57.9 % female, with mean (standard deviation, SD) age 42.1 (13.2) years and mean (SD) BMI 27.9 (6.7) kg/m^2^ (Table [2](#Tab2){ref-type="table"}). Self-identified race distributions were 77.1 % "Caucasian or White", 16.5 % "African American or Black", and four other self-identified race categories comprising 6.5 % of participants. Only a small fraction of TES participants self-identified as Hispanic ethnicity (3.8 % of total participants). Most (76.9 %) TES participants were current smokers with mean (SD) CPD of 16.0 (8.9). Age, self-identified race, and education distributions differed significantly by smoking status (current smokers were significantly more likely to be older, self-identify as Black, and significantly less likely to have a college degree), while sex, BMI, and self-identified ethnicity (Hispanic versus Not Hispanic) did not differ by smoking status.Table 2TES demographics and smoking status, overall and among those with and without banked biospecimensCharacteristicAllWithWithout*χ* ^2^ or *t*, *P*Sex^a^2.33, .13 Female2698 (57.9)1754 (57.1)944 (59.4) Male1964 (42.1)1319 (42.9)645 (40.6)Age (Years)^b^42.1 (13.2)42.5 (13.0)41.2 (13.5)3.0, .002 21--341497 (32.1)927 (30.2)570 (35.9)16.83, .0002 35--491781 (38.2)1222 (39.8)559 (35.2)  ≥ 501384 (29.7)924 (30.1)460 (28.9)BMI (kg/m^2^)^c^27.9 (6.7)28.1 (6.8)27.5 (6.5)2.6, .009  \< 251803 (38.7)1161 (37.8)642 (40.4)3.05, .08  ≥ 252859 (29.7)1912 (30.1)947 (59.6)Self-identified Race^e^26.5, \<.0001 White3578 (77.1)2420 (79.1)1158 (73.2)23.8, \<.0001^d^ Black765 (16.5)447 (14.6)318 (20.1) Other121 (2.6)80 (2.6)41 (2.6) Multi-racial73 (1.6)48 (1.6)25 (1.6) Native American67 (1.4)44 (1.4)23 (1.5) Asian24 (0.5)12 (0.4)12 (0.8)Ethnicity^f^0.07, .79 Hispanic178 (3.8)119 (3.9)59 (3.7) Not Hispanic4458 (96.2)2937 (96.1)1521 (96.3)Education^g^4.0, .26  \< High School356 (7.7)230 (7.6)126 (8.0) HS/some College3292 (71.3)2199 (72.2)1093 (69.5)  ≥ Bachelors969 (21.0)615 (20.2)354 (22.5)Smoking status0.35, .55 Non-smoker1077 (23.1)718 (23.4)359 (22.6) Smoker3585 (76.9)2355 (76.6)1230 (77.4)^a^ *χ* ^2^ ~smoking\ status~ = 1.22, *P* = .27.^b^ *t* ~smoking\ status~ = 3.2, P = .001. ^c^ *t* ~smoking\ status~ = 1.33, *P* = .18. ^d^White and Black. ^e^All races, *χ* ^2^ ~smoking\ status~ = 5.81, P = .016. ^f^ *χ* ^2^ ~smoking\ status~ = 2.04, *P* = .15. ^g^ *χ* ^2^ ~smoking\ status~ = 223, *P* = \<.0001

TES banked biospecimen availability and smoking status {#Sec7}
------------------------------------------------------

Two-thirds (66 %) of TES participants have banked biospecimens. PBMCs are the most common biospecimen type while urine is the least common (Table [3](#Tab3){ref-type="table"}). Among participants with banked biospecimens, and among the four biospecimen types, there are no significant differences in sex, age and BMI proportions, but there are significant differences in smoking status (Table [4](#Tab4){ref-type="table"}). Compared to participants with banked PBMC biospecimens, participants with banked urine biospecimens are significantly more likely to be smokers (*OR* = 1.26, 95 % CI 1.11--1.44, *P* = 0.0004).Table 3TES banked biospecimen aliquots, by biospecimen typeAliquots per participantPBMC^a^RBC^b^Plasma^c^Urine^d^Total1 Aliquot409429143212 Aliquots292390522993 Aliquots1771Total N Aliquots588672172914491920936Total N participants with Aliquots29632770291426203073^a^From one 8.5 mL ACDA yellow-top tube processed in two vials. ^b^From one 10 mL K~2~EDTA tube processed into three vials. ^c^From one 10 mL K~2~EDTA tube of whole blood processed into two vials. ^d^Aliquots of 100 mL from a 24 h urine sampleTable 4TES banked biospecimen availability, by biospecimen type, and by strata previously used for analysisAnyPBMCRBCPlasmaUrine30732963277029142620Smoking status Smoker2355 (76.6)2272 (76.7)2120 (76.5)2223 (76.3)2112 (80.6) Non-user718 (23.4)691 (23.3)650 (23.5)691 (23.7)508 (19.4)Sex Female1714 (55.8)1686 (56.9)1582 (57.1)1648 (56.6)1495 (57.1) Male1359 (44.2)1279 (43.1)1188 (42.9)1266 (43.4)1125 (42.9)Age (years) 21--34927 (30.2)880 (29.7)822 (29.7)876 (30.1)783 (29.9) 35--491222 (39.8)1184 (40.0)1109 (40.0)1171 (40.2)1057 (40.3)  ≥ 50924 (30.1)899 (30.3)839 (30.3)867 (29.8)780 (29.8)BMI, kg/m^2^  \< 251161 (37.8)1117 (37.7)1046 (37.8)1092 (37.5)1000 (38.2)  ≥ 251912 (62.2)1846 (62.3)1724 (62.2)1822 (62.5)1620 (61.8)Pearson *χ* ^2^, by biospecimen type: Smoking Status, *χ* ^2^ = 19.59 (*P* = .00021); Sex, *χ* ^2^ = 0.22 (*P* = .97); Age, *χ* ^2^ = 0.44 (*P* = .99); BMI, *χ* ^2^ = 0.29 (*P* = .96)

TES demographics {#Sec8}
----------------

Participants with banked biospecimens are significantly older (age, continuous or categorical), have significantly increased BMI (continuous), and are more likely to self-identify as White compared to those without (Table [2](#Tab2){ref-type="table"}). When stratified by ethnicity and race, self-identified non-Hispanic Black participants with banked biospecimens are significantly older and have significantly increased BMI than those without biospecimens \[mean (SD) age 40.8 (10.7) vs 38.8 (11.1) years, *t* = 2.45, *P* = 0.0144, *N* = 755; mean (SD) BMI 30.5 (8.0) vs 28.5 (6.9) kg/m^2^, *t* = 3.58, *P* = 0.0004, *N* = 755, data not shown\]. Significant differences in age and BMI among all participants and stratified by self-identified ethnicity and race are small (Cohen's *d*-values = 0.10, 0.09, 0.18 and 0.27, respectively). Smoking duration, CPD (continuous and categorical), and usual cigarette FTC tar level (categorical) are significantly increased in those with banked biospecimens compared to those without, overall, and when stratified by self-identified race (Table [5](#Tab5){ref-type="table"}). Significant differences are small; *d*-values for smoking duration overall, and among self-identified non-Hispanic Blacks and Whites are 0.13, 0.22 and 0.08, respectively, and *d*-values for CPD among self-identified non-Hispanic smokers, and among self-identified non-Hispanic White smokers, are 0.14 and 0.09, respectively.Table 5TES self-reported BOE, non-Hispanic current smokers by self-identified race, and by banked biospecimensCharacteristicAllWithWithout*χ* ^2^ or *t*, *P*Years smoked \[N (%)\]^a^22.0 (12.9)22.6 (12.8)20.9 (13.0)3.62, .0003 Black18.6 (11.8)19.7 (11.8)17.1 (11.5)2.69, .0074 White22.8 (13.0)23.1 (13.0)22.0 (13.2)2.05, .0404CPD \[N (%)\]^b^16.3 (8.9)16.7 (8.9)15.5 (8.9)3.60, .0003 Black11.3 (6.3)11.4 (6.4)11.1 (6.1)0.61, .5393 White17.4 (9.1)17.6 (9.0)16.8 (9.2)2.13, .0329CPD^c^ 1--10952(28.8)579 (26.6)373 (33.1)17.7, .0005 11--201487 (45.0)996 (45.8)491 (43.6) 21--30643 (19.5)453 (20.8)190 (16.9)  ≥ 31221 (6.7)148 (6.8)73 (6.5)Black 1--10327 (54.0)179 (52.7)148 (55.6)0.705, .8720 11--20227 (37.5)130 (38.2)97 (36.5) 21--3043 (7.1)26 (7.7)17 (6.4)  ≥ 319 (1.5)5 (1.5)4 (1.5)White 1--10625 (23.2)400 (21.8)225 (26.1)7.701, .0526 11--201260 (46.7)866 (47.2)394 (45.8) 21--30600 (22.3)427 (23.3)173 (20.1)  ≥ 31212 (7.9)143 (7.8)69 (8.0)FTC tar, mg^d^9.16 (5.4)9.18 (5.3)9.13 (5.6)0.23, .8187 Black10.9 (6.9)10.7 (6.9)11.2 (6.9)--0.74, .4622 White8.8 (5.0)8.9 (4.9)8.5 (5.0)1.86, .0624  ≤ 2.9472 (14.3)314 (14.4)158 (14.0)13.28, .0041 3--6.9887 (26.8)551 (25.3)336 (29.8) 7--12.9985 (29.8)689 (31.6)296 (26.2)  ≥ 13965 (29.2)627 (28.8)338 (30.0)Black  ≤ 2.9135 (22.3)81 (23.8)54 (20.3)1.35, .7183 3--6.976 (12.5)40 (11.8)36 (13.5) 7--12.974 (12.2)40 (11.8)34 (12.8)  ≥ 13321 (53.0)179 (52.7)142 (53.4)White  ≤ 2.9337 (12.5)233 (12.7)104 (12.1)14.62, .0022 3--6.9811 (30.0)511 (27.8)300 (34.8) 7--12.9911 (33.7)649 (35.3)262 (30.4)  ≥ 13644 (23.8)448 (24.3)196 (22.7)^a^ *N* = 3274. ^b^Cigarette butts returned, 24 h, *N* = 3303. ^c^FTND coding (1--10 = 0, 11--20 = 1, 21--30 = 2, \>30 = 3). ^d^  *N* = 3309

TES BOE {#Sec9}
-------

Most tobacco-specific (NE, serum cotinine and total NNAL) and non-specific BOE are significantly higher in smokers with banked biospecimens than in smokers without, except for serum cotinine, 4-ABP and MHBMA (Table [6](#Tab6){ref-type="table"}). Metabolites of acreolein and 1,3 butadiene are significantly greater in non-users with banked biospecimens than in non-users without. All statistically significant differences in BOE by banked biospecimen availability have small effect sizes, ranging from 0.10 to 0.24. When stratified by self-identified ethnicity and race, more BOE differ significantly by biospecimen availability among non-Hispanic Whites than among non-Hispanic Blacks (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}). The effect sizes of the two BOE differences in self-identified non-Hispanic Black smokers are small, and the effect size of the one BOE difference in self-identified non-Hispanic Black non-users is a medium effect size (*d* = 0.47). Among self-identified non-Hispanic White smokers, NE, total NNAL, carboxyhemoglobin and an acreolin metabolite, and among self-identified non-Hispanic White non-users, a 1,3 butadiene metabolite, exhibit significant differences. All these significant differences are of small effect size.Table 6TES laboratory-based BOE^a^ among smokers and non-users, and among those with and without banked biospecimensAllWithWithout*tPAmong smokers*NE per cig^b^0.89 (0.7)0.91 (0.7)0.86 (0.7)2.33.020NE mg/24 hr^c^12.78 (7.9)13.3 (7.9)11.76 (7.8)5.48\<.0001Serum cotinine ng/ml^d^188.9 (103.4)190.0 (103.1)186.7 (147.7)0.9.37Total NNAL ng/cig^e^29.4 (23.7)30.3 (23.9)27.8 (23.1)3.03.0025Total NNAL ng/24 hr^f^425.2 (303.9)445.5 (308.2)385.7 (291.5)5.67\<.0001COHb % saturation^g^5.26 (2.3)5.35 (2.3)5.09 (2.3)3.25.00121-OHP ng/24 hr^h^259.8 (345)268.3 (343)243.3 (349)2.32.023-HPMA ug/24 hr^i^1941.9 (1326)2017.6 (1302)1796.6 (1361)4.73\<.00014-ABP pg/g Hb^j^43.5 (53.6)44.2 (56.8)42.3 (47.1)0.96.34MHBMA ug/24 hr^k^3.52 (3.3)3.60 (3.3)3.38 (3.4)1.87.062DHBMA ug/24 hr^l^530.1 (276.3)541.1 (255.7)508.9 (311.2)3.11.0019*Among non-smokers*COHb % saturation^m^1.46 (0.5)1.46 (0.6)1.45 (0.5)0.08.943-HPMA ug/24 hr^n^461.7 (532)484.3 (571)416.3 (441.0)2.14.0334-ABP pg/g Hb^o^14.5 (70.8)13.2 (71.5)17.0 (69.6)−0.68.5MHBMA ug/24 hr^p^0.49 (1.0)0.48 (0.8)0.50 (1.3)−0.16.88DHBMA ug/24 hr^q^385.6 (172.5)398.8 (182.3)359.1 (147.7)3.82\<.0001^a^Definitions (and parent compounds) of BOE from Additional file [2](#MOESM2){ref-type="media"}: Table S1: *NE* Nicotine Equivalents (Nicotine); *Total NNAL* Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and its glucuronide (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone); *COHb* carboxyhemoglobin (carbon monoxide); *1-OHP* Total 1-hydroxypyrene (polycyclic aromatic hydrocarbons); *3-HPMA* 3-hydroxy-propylmercapturic acid (acreolein); *4-ABP* 4-aminobiphenyl hemoglobin (Hb) adducts (4-aminobiphenyl); *MHBMA* monohydroxyl-butenylmercapturic acid (1,3 butadiene); DHBMA = dihydroxy-butyl-mercapturic acid (1,3 butadiene)^b^ *N* = 3529, *d* = 0.10. ^c^ *N* = 3535, *d* = 0.18. ^d^ *N* = 3469. ^e^ *N* = 3529, *d* = 0.11. ^f^ *N* = 3535, *d* = 0.20. ^g^ *N* = 3558, *d* = 0.11. ^h^ *N* = 3554, *d* = 0.07. ^i^ *N* = 3556, *d* = 0.17. ^j^ *N* = 2801. ^k^ *N* = 3415. ^l^ *N* = 3558, *d* = 0.11. ^m^ *N* = 1069. ^n^ *N* = 1058, *d* = 0.13. ^o^ *N* = 723. ^p^ *N* = 629. ^q^ *N* = 1074, *d* = 0.24Table 7TES Non-Hispanic Black laboratory-based BOE by smoking status, and by banked biospecimen availabilityAllWithWithout*tPAmong smokers*NE per cig^a^1.04 (0.8)1.05 (0.8)1.02 (0.9)0.49.6254NE mg/24 hr^a^10.3 (6.7)10.6 (6.6)9.82 (6.7)1.46.1449Serum cotinine ng/ml^b^205.3 (113)206.8 (114.5)203.2 (111.2)0.37.7081Total NNAL ng/cig^c^33.4 (27.5)34.8 (28.0)31.5 (26.8)1.47.1414Total NNAL ng/24 hr^3^331.8 (233.9)349.7 (236.9)308.6 (228.3)2.13.0336COHb % saturation^d^4.74 (2.1)4.75 (2.1)4.74 (2.1)0.08.93551-OHP ng/24 hr^e^326.4 (421)333.8 (379.8)316.9 (469)0.47.63523-HPMA ug/24 hr^f^1605 (1083)1670 (1005)1521 (1172)1.64.10124-ABP pg/g Hb^g^39.6 (28.2)40.1 (29.8)39.0 (26.6)0.41.6831MHBMA ug/24 hr^h^2.65 (2.8)2.9 (3.2)2.3 (2.1)2.75.0062DHBMA ug/24 hr^i^495.5 (270.2)511.7 (276.9)474.4 (260.4)1.67.0946*Among non-smokers*COHb % saturation^j^1.5 (0.7)1.49 (0.7)1.52 (0.6)−0.24.81163-HPMA ug/24 hr^k^433.5 (379.8)458.8 (430.1)380.3 (237.3)1.43.15464-ABP pg/g Hb^l^12.9 (16.6)14.7 (19.7)9.24 (5.7)1.96.054MHBMA ug/24 hr^m^0.57 (0.9)0.64 (1.1)0.42 (0.6)1.41.1619DHBMA ug/24 hr^n^401.3 (177)426.3 (188.3)349.2 (138.8)2.83.0054^a^ *N* = 574. ^b^ *N* = 576. ^c^ *N* = 593. ^d^ *N* = 603. ^e^ *N* = 603. ^f^ *N* = 601. ^g^ *N* = 478. ^h^ *N* = 569. ^i^ *N* = 598. ^j^ *N* = 148. ^k^ *N* = 149. ^l^ *N* = 87. ^m^ *N* = 103. ^n^ *N* = 151Table 8TES non-Hispanic White laboratory-based BOE, by smoking status, and by banked biospecimen availabilityAllWithWithout*tPAmong smokers*NE per cig^a^0.86 (0.6)0.88 (0.6)0.82 (0.6)2.4.0166NE mg/24 hr^b^13.5 (8.1)14.0 (8.1)12.6 (8.1)4.01\<.0001Serum cotinine ng/ml^c^187.1 (101.2)188.1 (100.6)184.9 (102.6)0.75.4545Total NNAL ng/cig^d^28.4 (22.4)29.2 (22.4)26.7 (22.1)2.7.0069Total NNAL ng/24 hr^e^450.9 (314.2)467.1 (315.6)416.2 (308.5)3.91\<.0001COHb % saturation^f^5.43 (2.3)5.49 (2.3)5.29 (2.4)2.12.03431-OHP ng/24 hr^g^300.4 (362.3)307.1 (361.0)286.3 (364.7)1.38.16693-HPMA ug/24 hr^h^2048 (1368)2100 (1337)1936 (1427)2.89.00394-ABP pg/g Hb^i^45.2 (59.6)45.7 (62.3)44.1 (53.6)0.6.5475MHBMA ug/24 hr^j^3.78 (3.4)3.76 (3.2)3.82 (3.7)−0.39.6985DHBMA ug/24 hr^k^541.6 (281.2)548.3 (252.9)527.4 (333.4)1.63.1029*Among non-smokers*COHb % saturation^l^1.44 (0.5)1.44 (0.5)1.44 (0.4)0.07.94493-HPMA ug/24 hr^m^463 (557.3)480.2 (595)429.3 (474.6)1.35.17914-ABP pg/g Hb^n^15.1 (78.1)13.1 (79.3)18.7 (76.0)−0.83.4085MHBMA ug/24 hr^o^0.47 (1.0)0.44 (0.7)0.53 (1.5)−0.71.4782DHBMA ug/24 hr^p^386.1 (170.6)397.1 (180.1)364.7 (148.5)2.8.0053^a^ *N* = 2680. ^b^ *N* = 2686. ^c^ *N* = 2635. ^d^ *N* = 2667. ^e^ *N* = 2673. ^f^ *N* = 2680. ^g^ *N* = 2683. ^h^ *N* = 2681. ^i^ *N* = 2119. ^j^ *N* = 2590. ^k^ *N* = 2684. ^l^ *N* = 846. ^m^ *N* = 837. ^n^ *N* = 589. ^o^ *N* = 484. ^p^ *N* = 848

TES BOPH {#Sec10}
--------

The distribution of BOPH by banked biospecimen availability is shown in Table [9](#Tab9){ref-type="table"}. Six of 29 BOPH measures have nominally significantly higher levels in TES participants with available banked biospecimens versus those without, while the respiratory function measure FVC and hemoglobin remain significantly different after false discovery rate correction (*q*-values = 0.0128 and 0.0496, respectively) \[[@CR31]\]. After excluding individuals with implausible FEV~1~ values \< 35 % or \> 125 % of predicted, as suggested by Frost-Pineda *et al.* \[[@CR3]\], and then stratifying by self-identified ethnicity and race, and then by smoking status, we observed that self-identified non-Hispanic White smokers with banked biospecimens have significantly increased FVC compared to those without \[93.9 (23.2) vs 90.8 (17.9), *t =* 3.81, *P =* 0.0001, *N* = 2584\]. The statistically significant increase in % predicted FVC among self-identified non-Hispanic White smokers with available biospecimens is unexpected because multiple BOE are significantly increased in self-identified non-Hispanic White smokers with banked biospecimens and lung function is expected to be reduced in individuals with increased measures of exposure. Evidence for the influence of current smoking on longitudinal decline in FEV~1~ and FVC suggests that current smoking influences longitudinal FEV~1~ decline more than FVC \[[@CR32]\], though this would not explain an increase in FVC. We constructed another regression model including education and household income, but these potential confounders \[[@CR33]\] had no effect on the observed differences in FVC within non-Hispanic White smokers (data not shown). Further analyses of lung function measures and other variables in the TES may identify possible explanatory factors or confounders. After stratifying by self-identified race and ethnicity, and then by smoking status, we observed that self-identified non-Hispanic White non-users exhibit a significant difference in hemoglobin by banked biospecimen availability \[14.50 (1.42) vs 14.31 (1.25), *t =* 1.84, *P =* 0.033, *N* = 828\]. Statistically significant differences in FVC and hemoglobin in these strata are small (*d*-values are 0.15 and 0.14, respectively).Table 9TES participant BOPH, by banked biospecimen availabilityAnalyteWithWithoutN*tP*8-*epi*-prostaglandin-F~2α~ ^a^1745 (1000)1657 (1056)45572.74.006Total bilirubin^b^0.48 (0.3)0.49 (0.3)4420−0.92.36Hematocrit (%)43.2 (4.1)42.9 (4.1)45602.61.01Hemoglobin^c^14.7 (1.52)14.6 (1.50)45722.74.003Platelets (10^3^/uL)275.2 (70.2)277.9 (71.0)4527−1.25.21WBC (10^3^/uL)7.68 (2.3)7.61 (2.2)45720.99.32Microalbumin (mg/24 h)43.7 (338.3)31.6 (188.4)32351.31.1911-dehydrothromboxane-B~2~ ^1^1343.0 (931)1277.2 (1027)42862.05.04hs-CRP (mg/L)4.45 (7.0)4.25 (6.4)44330.92.36Fibrinogen^b^323.8 (75.8)320.1 (77.7)44981.56.12von Willebrand Factor (%)102.8 (46.1)100.9 (48.6)46011.26.21Serum creatinine^b^0.82 (0.2)0.81 (0.2)46400.32.75Blood urea nitrogen^b^13.5 (4.4)13.1 (4.5)46402.39.02Total cholesterol^b^196.8 (40.9)194.6 (42.3)46391.68.09HDL^b^52.2 (16.3)52.6 (16.2)4590−0.95.34LDL^b^115.3 (35.0)113.5 (37.4)44281.60.11Triglycerides^b^153.9 (125)148.9 (125)46391.29.19Alkaline phosphatase^d^74.9 (25.3)74.9 (26.1)4637−0.02.99Alanine aminotransferase^d^26.1 (24.7)26.5 (24.1)4617−0.45.65Aspartate aminotransferase^d^24.8 (19.0)25.4 (21.1)4561−0.96.34Lactate dehydrogenase^d^154.8 (32.8)153.1 (32.2)44821.63.10FEV~1~ (% of predicted)85.1 (21.7)84.7 (20.9)45390.48.63FVC (% of predicted)94.4 (25.1)91.8 (22.0)45413.52.0004Serum albumin^c^4.31 (0.4)4.30 (0.3)46290.27.79Serum glucose^b^96.8 (30.7)97.1 (29.8)4626−0.29.77Uric acid^b^5.28 (1.5)5.26 (1.4)46400.40.69Diastolic BP (mmHg), Visit 177.0 (10.7)76.5 (10.3)46591.26.21Diastolic BP (mmHg), Visit 276.5 (10.3)76.5 (10.2)4660−0.05.96Systolic BP (mmHg), Visit 1123.5 (16.6)122.6 (16.0)46591.78.07Systolic BP (mmHg), Visit 2121.5 (15.9)120.8 (15.5)46601.32.19Heart rate (bpm), Visit 172.7 (10.2)72.8 (10.2)4656−0.12.90Heart rate (bpm), Visit 273.4 (10.3)72.9 (10.4)46591.44.15^a^ng/24 hrs. ^b^mg/dL. ^c^g/dL. ^d^U/L

TES participant usual cigarette brand {#Sec11}
-------------------------------------

Information on participant's usual cigarette brand is available from 606 and 1336 self-identified non-Hispanic Black and non-Hispanic White smokers, respectively. The top 20 brands account for 66.0 and 49.4 % of the brand information available from self-identified non-Hispanic Black and non-Hispanic White smokers, respectively (Table [10](#Tab10){ref-type="table"}). Usual cigarette brand distributions do not differ significantly among self-identified non-Hispanic Black or among non-Hispanic White smokers by the presence or absence of banked biospecimens (Table [10](#Tab10){ref-type="table"}).Table 10TES participant usual cigarette brand, by self-identified race/ethnicity and by banked biospecimen availabilityUsual cigarette brand identificationAllWith \[N, %\]Without \[N, %\]Self-identified non-Hispanic Black smokers^a^Newport KFMHP 2631011015150.55049.5Newport 100's 100FMHP643554.72943.5Carlton menthol KFMSP261765.4934.6Newport KFMSP 278012231252.21147.8Carlton 100's 100FHP201050.01050.0Carlton 100's 100FSP18950.0950.0Newport 100's 100FMSP17741.21058.8Carlton 100's menthol 100FMSP161275.0425.0Carlton 100's menthol 100 FMSP15960.0640.0Carlton KFSP12866.7433.3Benson & Hedges 100's menthol 100FMSP11981.8218.2Kool filter kings KFMHP11763.6436.4Merit ultra lights KFHP11436.4763.6Kool filter king KFMSP9666.7333.3Kool super longs 100's 100 FMHP9444.4555.6Kool super longs 100's 100FMSP9555.6444.4Merit ultima 100's 100FHP8562.5337.5Now 100 s menthol 100 FMSP8562.5337.5Carlton KFHP6466.7233.3Doral full flavor 100's menthol 100FMSP6350.0350.0Total40022255.517844.5Self-identified non-Hispanic White smokers^b^Marlboro lights KFHP22716070.56729.5Marlboro ultra lights KFHP18612466.76233.3Marlboro KFHP14710370.14429.9Marlboro ultra lights 100's 100FHP1067066.03634.0Marlboro lights 100's 100FHP906875.62224.4Camel Turkish lights KFHP815567.92632.1Carlton 100's 100FHP674668.72131.3Marlboro 100's 100FHP614268.91931.1Carlton 100's 100FSP472859.61940.3Camel filters KFHP412663.41536.6Carlton KFSP352674.3925.7Newport KFMHP 263101332575.8824.2Now 100 s 100FSP312477.4722.6Doral ultra lights 100's 100FHP301963.31136.7Virginia slims ultra lights menthol 100FMHP291965.51034.5Benson & Hedges deluxe ultra lights 100's 100FHP261246.21453.9Now 100 s menthol 100FMSP262180.8519.2Carlton 100's menthol 100FMSP252080.0520.0Marlboro KFSP241770.8729.2Virginia slims ultra lights 100FHP241875.0625.0Total133692369.141330.9^a^χ^2^ ~19d.f.~ = 13.85, *P* = .79. ^b^ *χ* ^2^ ~19d.f.~ = 18.34, *P* = .50

Modeling banked biospecimen availability by demographics, BOE and BOPH {#Sec12}
----------------------------------------------------------------------

Sample sizes among self-identified non-Hispanic Black and White smokers with complete data and with imputed data for the progressively more complex models were 3236 and 3318 (2.5 % of participants had missing data in Model 1), 2317 and 3318 (30.2 % of participants had missing data in Model 2), and 1090 and 3053 (64.3 % had missing data in Model 3), respectively. However, while a large fraction of the population was missing one or more variable values, on average they were only missing a single value out of a large number of independent variables. The number of missing values that were imputed was relatively small; 0.3 % of all values required imputation in Model 1, 1.9 % in Model 2, and 2.5 % in Model 3. Significant demographic variables, BOE and BOPH in progressively more complex multivariate models of banked biospecimen availability with imputed data were: Model 1) BMI, self-identified race, age and age squared; Model 2) self-identified race, age, age squared, and NE/24 h; and Model 3) self-identified race, age, age squared, NE/24 h, serum cotinine, MHBMA and FVC (Table [11](#Tab11){ref-type="table"}). The mean (SD) predicted probabilities of banked biospecimen availability, in progressively more complex multivariate models without and with imputed data are: Model 1) 0.647 (0.069) and 0.665 (0.060); Model 2) 0.643 (0.077) and 0.668 (0.070); and Model 3) 0.625 (0.102) and 0.669 (0.095). Explanatory power estimates (r^2^) of the anthropometric, demographic, BOE and BOPH variables in progressively more complex multivariate models with imputed data among self-identified non-Hispanic Black and White smokers to predict banked biospecimen availability are 0.018, 0.024, and 0.037, respectively. In permutation analyses of self-identified non-Hispanic Black and White smokers with imputed data in Model 3, the mean (95 % confidence interval) r^2^ was 0.020 (0.016 - 0.023) suggesting that about half of the explanatory power of variables is due to random variability (0.020/0.037 = 0.54).Table 11Multivariate model of banked biospecimen availability, self-identified non-Hispanic black and non-Hispanic white smokers*β*SE*tP*FMI^a^Sex0.1910.1231.5500.1210.009BMI^b^0.0150.0081.8600.0630.010Self-identified race−0.5980.125−4.7800.0000.006Education (HS/some College)0.0010.1460.0100.9930.011Education (≥Bachelors)−0.1290.173−0.7400.4570.010Age0.0570.0202.8000.0050.003Age squared−0.0010.000−2.9300.0030.003Smoking duration0.0070.0061.2800.2010.03111--20 CPD0.1010.1140.8900.3740.00921--30 CPD0.1430.1620.8800.3790.010\>30 CPD0.2150.2430.8800.3770.020CPD^b^0.0010.0090.0700.9440.011FTC tar−0.0020.008−0.3000.7670.004Nicotine equivalents/cigarette−0.0850.162−0.5300.5990.042Nicotine equivalents/24 h0.0340.0152.3500.0190.028Serum cotinine−0.0010.001−2.0700.0380.027Total NNAL/cigarette0.0060.0051.2200.2240.034Total NNAL/24 h0.0000.000−0.1900.8490.025Carboxyhemoglobin−0.0190.027−0.7000.4860.0071-OHP0.0000.0000.0000.9990.0053-HPMA0.0000.0000.0100.9900.0104-ABP0.0010.0010.8400.4000.317MHBMA−0.0300.015−1.9800.0480.069DHBMA0.0000.000−0.8200.4100.0068-*epi*-prostaglandin-F~2α~ ^b^0.0000.000−0.6300.5270.010Total bilirubin−0.1470.177−0.8300.4060.051Hematocrit0.0180.0260.6800.4950.027Hemoglobin−0.0710.077−0.9300.3510.024Platelets−0.0010.001−1.2800.2000.051WBC−0.0070.020−0.3700.7150.026Microalbumin0.0000.0000.9600.3410.40911-dehydrothromboxane-B~2~0.0000.0000.7200.4720.108hs-CRP0.0070.0071.0200.3060.072Fibrinogen0.0000.0010.5600.5750.052von Willebrand factor0.0000.0010.2600.7980.019Serum creatinine0.2200.2590.8500.3960.021Blood urea nitrogen−0.0040.011−0.3600.7200.005Total cholesterol0.0210.1380.1600.8770.030HDL−0.0190.138−0.1400.8900.030LDL−0.0220.138−0.1600.8720.030Triglycerides−0.0040.028−0.1500.8820.031Alkaline phosphatase−0.0010.002−0.8400.4010.009Alanine aminotransferase0.0010.0030.3800.7000.012Aspartate aminotransferase−0.0060.004−1.5800.1130.022Lactate dehydrogenase0.0030.0011.8800.0600.041FEV~1~ excluding extreme values^b^−0.0030.003−0.9300.3520.002FVC excluding extreme values^b^0.0100.0034.0300.0000.003Serum albumin0.1780.1411.2600.2060.022Serum glucose−0.0030.001−1.8500.0650.019Uric acid−0.0270.037−0.7300.4640.004Diastolic BP, Visit 10.0050.0060.8300.4050.003Diastolic BP, Visit 2−0.0050.006−0.7600.4460.002Systolic BP, Visit 10.0000.0040.1000.9190.003Systolic BP, Visit 20.0030.0040.6800.4980.002Heart rate, Visit 1−0.0070.005−1.5000.1340.003Heart rate, Visit 20.0030.0050.5800.5630.003Constant−2.2430.988−2.2700.0230.006^a^Proportion of variability in the SE due to multiple imputation. ^b^lmputation truncated at observed values

Correlations of clinical chemistry results in 47 plasma samples from the SRI CAL (2013) and those from serum reported by the CRO (2002--2003) were high and statistically significant \[glucose (0.922), aspartate aminotransferase (0.993), alanine aminotransferase (0.997), total bilirubin (0.960), albumin (0.702), and total cholesterol (0.913), all p-values \< 0.001\] (Table [12](#Tab12){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). The lower correlation for blood albumin may be due to the two different matrices, the increased variance of some albumin clinical chemistry analysis methods \[[@CR34]\], or the use of different methods in the clinical analyzers in the two different clinical chemistry laboratories.Table 12Comparison of six circulating analytes in TES participant plasma and serumSRI CAL analyte values, plasmaCRO analyte values, serumGLU^a^AST^b^ALT^c^TBI^d^ALB^e^CHO^f^GLUASTALTTBIALBCHO894554951.84.4223823814031.194.219211720181.44.021311417181.054.020217322420.44.723816121370.284.52348445500.54.21848337370.233.91678630290.44.32028331270.284.418511927220.64.614211520190.414.61426522220.54.52076822210.384.42038531360.64.52378527380.364.62347032450.24.41636926390.184.414811316100.24.117611513110.164.01658522220.84.73047422200.604.82888038570.34.71607934520.244.61649417120.44.61489314110.274.31369424210.35.02319128220.224.92139318250.34.02389217270.274.223010321270.34.11739818230.294.21679327280.84.31459320240.554.01387923220.64.22177919190.484.72188319160.54.61748215130.334.31669322150.44.81498616140.244.31308526240.65.02627919180.294.62399325300.44.41767521310.234.21678115140.74.82145028210.474.92299118100.34.42118118100.184.32009026250.54.61778422210.334.41749236560.43.92289130500.214.02218413110.44.12327942250.264.22309016164.81238617130.154.61168221100.33.8196573970.254.21908225200.53.91598520170.293.71427448290.94.81816844240.404.416110742700.74.920010237600.514.81878822250.53.81678521200.343.91649025270.54.41838825270.344.61839827180.44.52079825180.274.31929444470.24.11638939440.164.11628920170.34.31399215100.304.31659332510.44.82258226420.244.52038115160.54.31817512120.264.21538153470.64.51537348410.394.31534515170.34.31201718160.164.41218923230.54.91687718180.324.41448633300.34.42678230230.164.425710116160.24.42398516150.134.32189033400.44.31778327340.274.31668426240.44.31758027230.254.31698814120.24.11539228270.184.7230^a^Glucose (mg/dL). ^b^Aspartate aminotransferase (U/L). ^c^Alanine aminotransferase (U/L). ^d^Total bilirubin (mg/dL). ^e^Albumin (g/dL). ^f^Total cholesterol (mg/dL)Fig. 1Comparison of six circulating analytes in TES plasma (CAL) and serum (CRO)

Mean (SD) DNA and RNA from \~1 M cells was 4.63 (1.63) ug, and 2.10 (0.62) ug, respectively. We sent four DNA samples from Gentra Puregene extraction and 27 DNA samples from NORGEN extraction for Smokescreen Array genotyping at the Rutgers University Infinite Biologics facility. All DNA samples had genotype completion rates ≥ 97.5 % and passed the 97 % rate threshold; the mean genotype completion rate was 99.4 %. Mean (SD) RNA Integrity (RIN) scores from 28 RNA samples analyzed were 6.4 (2.2); 68 % of RIN scores were ≥ 6.0, a standard used in RNA sequence analysis \[[@CR35]\]. There were no significant differences in sex, race, smoking status, or total nicotine equivalents between RNA samples with RIN ≥ 6.0 and \< 6.0 (all *p*-values \> 0.12). Thus, from PBMC pellets frozen at ultralow temperatures for over a decade, DNA quality and genotyping results were excellent, while RNA quality was good, but requires evaluation using transcriptome-wide methods.

Finally, we assessed statistical power to detect *a priori* genetic loci of interest from an example of a large-scale (1000 s) candidate gene association scan, and an example from a locus nominated by genome-wide association scans (GWAS), with genome-wide significance (GWS) as the statistical threshold. For self-identified non-Hispanic Black current smokers, we selected rs11187065 as an example, identified in the insulin-degrading enzyme gene as the gene-centric SNP most significantly associated with serum cotinine in the Coronary Artery Risk Development in Young Adults (CARDIA) study by Hamidovic *et al.* \[[@CR36]\]. The influence of rs11187065 on serum cotinine was substantial with a *β* of −85.1 ng/ml, with mean (SE) of 236.5 (8.1) ng/ml from 365 African American smokers \[[@CR36]\]. Mean (SD) CPD in the CARDIA sample was 10.5 (7.4), similar to that of the TES (Table [4](#Tab4){ref-type="table"}). Using the sample size of self-identified non-Hispanic Black smokers with banked PBMCs in the TES (*N* = 340), there is 57 % power to detect the locus at genome-wide significance (and 83 % power to detect this locus at the original study's Bonferroni adjustment level of 2.3 × 10^−6^) using an additive model, a one-sided test, the mean (SD) of serum cotinine among self-identified non-Hispanic Black smokers (Table [6](#Tab6){ref-type="table"}), the rs11187065 minor allele frequency of 0.083 in the HapMap \[[@CR37]\] African Americans in the Southwest sample, and the effect size from Hamidovic *et al*. For assessing power to detect *a priori* loci of interest among self-identified non-Hispanic White current smokers, we selected rs1051730 in the nicotinic acetylcholine receptor (nAChR) subunit gene cluster on chromosome 15q25.1, associated with smoking intensity and related phenotypes \[[@CR38]\], including cotinine level \[[@CR39]\], as an example. In an analysis of 2932 smokers with serum or plasma cotinine estimates, Munafo *et al.* estimated that each minor allele contributed to a mean increase in the unadjusted level of cotinine in European ancestry samples of 138.72 nmol/L \[(95 % CI) 97.91 - 179.53 nmol/L, *P* = 2.7 × 10^-11^\] \[[@CR39]\], or 24.42 ng/mL, although this was reduced 18 % upon adjustment for self-reported CPD. Using the sample size of self-identified non-Hispanic White smokers with banked PBMCs in the TES (*N* = 1840), there is 70--96 % power to detect this locus at a genome wide significance level (5 × 10^−8^) using an additive model, a one-sided test, the mean (SD) of serum cotinine among self-identified non-Hispanic White smokers (Table [7](#Tab7){ref-type="table"}), the rs1051730 minor allele frequency of 0.385 in HapMap Utah Residents with Northern and Western European Ancestry sample, and estimated allele effect sizes of Munafo *et al.* (adjusted and unadjusted for CPD).

Discussion {#Sec13}
==========

TES research opportunities {#Sec14}
--------------------------

TES data and banked biospecimens, together with current biotechnologies, offer opportunities for the tobacco research community to identify behavioral, clinical, environmental and molecular factors that may influence cigarette smoke exposures (susceptibility model) and identify molecular factors that may be modulated by cigarette smoke exposures (response model). In particular, the TES can provide existing BOE and BOPH data from a large sample of generally healthy individuals, as well as banked biospecimens for the generation of novel BOE and BOPH. We will conduct biomarker research in the context of an Analysis Consortium that will enhance the TES by adding novel biomarkers and biomarker analyses to elucidate relationships between cigarette smoke exposures and health effects. We will share data with other collaborations engaged in the analyses and meta-analyses of susceptibility and response models. We will deposit data with the repositories designed for genome-wide data per Federal guidance or journal practice and conditional on Human Subjects Committee approval.

Specifically, GWAS using TES PBMC DNA may contribute to the elucidation of relationships between germline variation and self-report and laboratory measures of exposures \[[@CR38], [@CR39]\], including genetic loci influencing the non-nicotine tobacco-specific BOE NNAL. Analyses of TES PBMC mitochondrial DNA (mtDNA) via copy number and deletion analysis \[[@CR40]\] may enhance knowledge of the factors that influence mtDNA damage \[[@CR41], [@CR42]\]. Analysis of PBMC DNA and RNA will provide additional data to examine the effects of cigarette smoking on the PBMC epigenome \[[@CR43], [@CR44]\] and transcriptome \[[@CR45]\]. Analyses of the plasma and urine proteome \[[@CR46], [@CR47]\] and metabolome \[[@CR48]--[@CR50]\], may make a contribution to the developing literature of the impact of tobacco and other exposures defining the *exposome*, an integrated approach to biomarker discovery for exposure and disease paradigms \[[@CR51]\]. Validation, integration and extension of these susceptibility and response models can be conducted in independent datasets and in meta-analyses, and may contribute to the development of biomarker panels for diagnostic, prognostic and therapeutic research in tobacco-attributable disease.

There are a number of differences in the landscape of smoking behaviors, tobacco/nicotine products and tobacco control between the time in which the TES was conducted and the present day \[[@CR52]\]. These differences include: 1) the prevalence of cigarette use in U.S. adults has declined from \~21 to \~18 %; 2) the regular use of electronic cigarettes has increased in prevalence from 0 to almost 3 %; 3) the annual spending on advertising of tobacco products in the U.S. has declined from an all-time high of \$15.4 billion in 2003 to \$9.6 billion in 2012; 4) there has been a substantial increase in restrictions on smoking in public places due to increased recognition of harm associated with exposure to second and third-hand smoke; and 5) the passage in 2009 of the Family Smoking Prevention and Tobacco Control Act which prohibited the use of terms in advertising related to "light" cigarettes and created a regulatory framework by which the FDA can evaluate new tobacco products prior to their marketing to the public. Even with these temporal differences, there are several similarities concerning the cigarettes themselves that are of most relevance to the present investigation of cigarette smoking and its impact on BOE and BOPH. These include: 1) despite various changes in cigarette design over the past 12 years, there is no evidence that any of these have resulted in a "safer" cigarette; 2) the amount of tar and nicotine in cigarettes has remained relatively stable since 1993; 3) the most popular brands of cigarettes smoked (see Table [10](#Tab10){ref-type="table"}) remain the same (Marlboro, Camel, and Newport); 4) the effects of exposure to combustible tobacco products both with respect to BOE and BOPH remain the same; and 5) the health consequences of exposure to cigarette smoke (either mainstream or sidestream) including cancer, cardiovascular disease, and respiratory disease remain the same. Since the primary focus of the present investigation is on BOE and BOPH that reside within pathways resulting in negative health outcomes, the TES remains as relevant today as in 2003.

TES biospecimens provide a sample of current smokers powered at GWS to identify the chr15q25.1 nAChR loci associated with BOE (cotinine levels \[[@CR39], [@CR53], [@CR54]\], and NNAL \[[@CR55]\]). These biospecimens may provide data for future meta-analyses of BOE in both European ancestry and African ancestry samples. TES participants who are current smokers, have smoking topography data, BOE and banked biospecimens are suitable subjects for pharmacogenetic or pharmacometabolic research, e.g., to identify drug metabolizing enzyme and transporter gene associations with existing tobacco-specific BOE, or with as yet undetermined metabolic profiles in 24-h urine. TES biospecimens and data can be used to identify or replicate novel susceptibility or response models, especially in collaborative meta-analyses. Such results may be validated in larger datasets focused on the analysis of tobacco exposures, such as the Population Assessment of Tobacco and Health (PATH) study \[[@CR56]\].

Limitations to the resource {#Sec15}
---------------------------

The TES was a multi-site, cross-sectional study with collection sites distributed across the U.S. The sample has limited numbers of individuals with self-identified race other than Black or White, and has limited numbers of individuals with self-identified ethnicity of Hispanic. The diversity in geographical collection is an opportunity to evaluate region as a covariate in both cigarette smoke exposure susceptibility and response-to-tobacco models, e.g., comparing BOE by region or state. However, regional diversity also represents a challenge for future analyses due to potential confounding. Some potential confounders can be measured at a molecular level and used as a covariate in analyses, e.g., principal components of population genetic variation \[[@CR57]\] can be evaluated by region or by state.

TES participants with banked biospecimens exhibit small statistically significant differences in demographics and biomarkers compared to TES participants without banked biospecimens. With respect to differences in demographics, participants with banked biospecimens were significantly older and more likely to self-identify as White. The smaller proportion of Black TES participants with banked biospecimens compared to White TES participants with banked biospecimens is consistent with contemporaneous observations in epidemiologic cohorts of reduced willingness to provide consent for future genetic testing in the National Health and Nutrition Examination Survey of 1999--2000 \[[@CR58]\], and reduced willingness to provide consent for storage of DNA for future genetic testing in the Baltimore Epidemiological Catchment Area study of 2004--2005 \[[@CR59]\], even though the TES was not a representative population-based survey based on national or local sampling. With respect to differences in exposure, smokers with banked biospecimens had increased NE per 24 h and reduced serum cotinine, consistent with the differences observed in demographic characteristics. Despite these small statistically significant differences in demographics and exposure between TES participants with and without biospecimens, TES participants with banked biospecimens can be selected by specific clinical and laboratory criteria to create defined datasets for molecular analyses.

Use and availability of TES data and biospecimens {#Sec16}
-------------------------------------------------

The principal intended result of any analysis of the TES is the generation of knowledge related to smoking and health that is shared with the public health community and in the scientific peer-reviewed literature. SRI and the VTHRR agreed on the following principles regarding use of TES data and biospecimens. First, maintain the integrity of the data and samples, i.e., establish infrastructure to track and make the data and biospecimens secure. Second, ensure that potential users of the TES data and/or biospecimens are scientific researchers or organizations focused on the intended analysis goals of the TES, as assessed by education, experience, or by publication track record. Third, include terms in Material Transfer Agreements requiring recipients of data and/or samples to make reasonable efforts to publish the results of studies approved after scientific advisory committee review in the peer-reviewed scientific literature. Under data-sharing guidance for researchers using Federal (e.g., NIH) funds \[[@CR60]--[@CR62]\] and an Office of Science and Technology Policy memorandum \[[@CR63]\], scientists who generate molecular data, using array-based or high-throughput genomic technologies are obligated to submit both phenotype and molecular data to qualifying databases.

This is the first time that TES data and biospecimens will be made available to independent scientists in any life sciences area. There is a need for careful, objective scientific analysis of the resource. Consistent with the 2012 recommendation of the U.S. Institute of Medicine to incorporate an independent Tobacco Research Governance Entity \[[@CR64]\], SRI has engaged leading experts to form a TES Scientific Advisory Board. This board will provide oversight, review and adjudication of research applications to use the TES data and biorepository resources.

Due to the large size of the TES research resource and the possibilities for integrative analyses, we emphasize our interest in collaborating with individual or groups of investigators, institutions and/or sponsors. Analysis of multiple domains of molecular signatures from TES biospecimens will elucidate the contribution of the genome to exposure susceptibility and the subsequent response of multiple --omic domains to cigarette smoke exposure. Investigators interested in collaborative or independent investigations using the TES data and biospecimens are encouraged to contact the SRI authors.

Conclusions {#Sec17}
===========

The TES research resource represents a sample of 4662 current cigarette smokers and tobacco product and nicotine non-users and includes: behavioral and demographic data; cigarette product characteristics; self-reported clinical data and laboratory-based BOE and BOPH; and banked biospecimens suitable for molecular analyses from \>3000 participants. We identified small but statistically significantly greater self-reported measures of cigarette consumption and NE in participants who had consented to contribute biospecimens for banking and future analysis, primarily in self-identified non-Hispanic White smokers, compared to those not contributing biospecimens. The sample of TES participants with biospecimens is statistically powered to provide information on existing susceptibility biomarkers in self-identified Blacks and in self-identified Whites, and represents a well-powered resource to identify novel biomarkers of susceptibility and response to cigarette smoke exposures. The TESAC will seek support to enable research efforts to generate and contribute --omic data to research consortia and to public databases, and findings to the peer-reviewed literature. Such findings will contribute to the understanding of the relationship between cigarette smoke exposures and attributable disease.
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Additional file 1:**Total Exposure Study inclusion and exclusion criteria.** (PDF 75 kb)Additional file 2: Table S1.Biomarkers of exposure in the Total Exposure Study. (PDF 353 kb)Additional file 3: Table S2.Biomarkers of potential harm in the Total Exposure Study. (PDF 191 kb)

TES

:   Total Exposure Study

BOE

:   Biomarkers of exposure

BOPH

:   Biomarkers of potential harm

U.S.

:   United States

VTHRR

:   Virginia tobacco and health research repository

BMI

:   Body mass index

FTC tar

:   Federal trade commission machine-rated tar

CROs

:   Clinical research organizations

TESAC

:   TES Analysis Consortium

KEDTA

:   Potassium ethylenediaminetetraacetic acid

ACDA

:   Acid citrate dextrose solution A

PBMC

:   Peripheral blood mononuclear cell

UCSF

:   University of California San Francisco

HIPAA

:   Health insurance portability and accountability act

CAL

:   Clinical analysis laboratory

NE

:   Total nicotine equivalents

LC-MS/MS

:   Liquid chromatography-mass spectrometry-mass spectrometry

NNAL

:   4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol

NNK

:   4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone

COHb

:   Carboxyhemoglobin

1-OHP

:   1-hydroxypyrene

3-HPMA

:   3-hydroxy-propylmercapturic acid

4-ABP

:   4-aminobiphenyl

Hb

:   Hemoglobin

GC-MS

:   Gas chromatography--mass spectrometry

MHBMA

:   Monohydroxyl-butenylmercapturic acid

DHMBA

:   Dihydroxy-butyl-mercapturic acid

BRFSS

:   Behavioral Risk Factor Surveillance System

EIA

:   Enzyme immunoassay

WBC

:   White blood cell

hs-CRP

:   High-sensitivity C-reactive protein

HDL

:   High-density lipoprotein

LDL

:   Low-density lipoprotein

BP

:   Blood pressure

FEV~1~

:   Forced expiratory volume in 1 second

FVC

:   Forced expiratory vital capacity

CPD

:   Cigarette per day

N

:   Total number

SD

:   Standard deviation

CARDIA

:   Coronary artery risk development in young adults

GWAS

:   Genome-wide association study

NHANES

:   National health and nutrition examination survey

nAChR

:   Nicotinic acetylcholine receptor

PATH

:   Population assessment of tobacco and health

IOM

:   Institute of medicine
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